HYPD
Hyperion DeFi, Inc.3.0800
+0.0000+0%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
25.17MP/E (TTM)
-Basic EPS (TTM)
-19.15Dividend Yield
0%Recent Filings
8-K
8-K
Hyperion partners for Hyperliquid validator, futures market
Hyperion DeFi entered a Joint Validator Agreement on October 27, 2025, with Kinetiq Group and Pier Two, effective June 25, 2025, to operate a co-branded validator node on Hyperliquid using 10,000 HYPE from its treasury. It also signed the HAUS Agreement on October 28, 2025, allocating 500,000 HYPE to Felix for launching a HIP-3 perpetual futures market, earning revenue shares and full staking rewards over a 52-week term. This bolsters Hyperion's HYPE holdings through new DeFi utilities. CEO Michael Rowe's resignation takes effect November 1.
8-K
ATM offering doubled to $100M
Hyperion DeFi expanded its at-the-market offering program on September 24, 2025, via an amendment with Chardan Capital Markets, doubling the aggregate offering price to $100 million. The company has already sold 4,176,196 shares for net proceeds of $29.0 million. This boosts capital access. Yet dilution risks loom for shareholders.
8-K
Nasdaq compliance regained; CEO resigns
Hyperion DeFi regained Nasdaq compliance on September 2, 2025, after boosting stockholders' equity above the $2.5 million threshold, averting delisting risks. That day, CEO Michael Rowe announced his resignation, with Hyunsu Jung stepping in as interim CEO, CFO, Treasurer, and Secretary for a smooth handover. The board expanded to six members, appointing Happy Walters—blockchain veteran and Blue Horizon Capital CEO—with 50,000 vesting RSUs. Leadership shakeup signals fresh strategic push in DeFi.
8-K
Hyperion DeFi doubles shares
Hyperion DeFi boosted its authorized common shares to 600 million and preferred to 60 million via charter amendment filed August 19, 2025, following shareholder approval at the August 18 annual meeting where 51.4% quorum participated. All directors were elected, auditors ratified, and executive pay approved advisory, while the written consent proposal fell short. This doubles issuance capacity for future financing. Yet dilution looms for existing holders.
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
HYFT
MindWalk Holdings Corp.
1.68-0.11
HYPMY
Hypera SA
4.10+0.05
HYPR
Hyperfine, Inc.
0.95+0.02
IRD
Opus Genetics, Inc.
2.14+0.01
KALA
KALA BIO, Inc.
0.56-0.05
KPRX
Kiora Pharmaceuticals, Inc.
2.04-0.02
OCS
Oculis Holding AG
19.84-0.63
OCUL
Ocular Therapeutix, Inc.
14.39+0.22
OPT
Opthea Limited
3.41+0.00